ARA-290 (Cibinetide)

Introduction

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the helix-B surface of erythropoietin. It was developed to preserve EPO's tissue-protective effects while eliminating its hematopoietic activity, which carries cardiovascular risk at supraphysiologic doses. Investigational in the United States.

Mechanism of Action

ARA-290 binds the Innate Repair Receptor (IRR), a heteromeric complex of the EPO receptor and the common β-chain (βcR). IRR engagement drives anti-inflammatory and tissue-reparative signaling without stimulating erythropoiesis.

Research Indications

The largest programs evaluate diabetic peripheral neuropathy and sarcoidosis-related small-fiber neuropathy, with reductions in pain scores and improvements in corneal nerve-fiber density reported in mid-phase trials. Additional research contexts include neuropathic pain, ocular surface disease, and post-surgical recovery.

Reconstitution

Typical 8 mg lyophilized vial: add 2 mL of bacteriostatic water, swirl gently until clear. Final concentration 4000 mcg/mL (4 mg/mL) — each 0.1 mL (10 units on a U-100 insulin syringe) delivers 400 mcg.

Dosing Protocol (research literature)

Published protocols typically dose 1–4 mg subcutaneously once daily, with 4 mg most common in neuropathy trials. Treatment duration 4–12 weeks; pain-score and nerve-fiber endpoints are usually reassessed at week 4 and again at end of treatment.

Administration

Subcutaneous injection into abdominal fat, rotating sites. Timing of day does not appear to influence efficacy.

Storage & Handling

Lyophilized: refrigerate (2–8°C). Reconstituted: refrigerate; stable approximately 21–28 days. Protect from light. Do not freeze reconstituted product.

Side Effects

Predominantly mild injection-site reactions. No significant elevation in hematocrit, hemoglobin, blood pressure, or thromboembolic events in published trials — the principal safety differentiators from EPO.

Contraindications

Active malignancy, pregnancy, lactation, uncontrolled hypertension, history of thromboembolic disease, and prior hypersensitivity.

Monitoring

Baseline CBC, blood pressure, and a validated neuropathy/pain instrument (e.g., NTSS-6, NPSI). Re-measure at 4, 8, and 12 weeks. Hematocrit and blood pressure surveillance remains prudent despite the non-erythropoietic profile.

Disclaimer

This article is for informational and research-reference purposes only. Nothing in this document constitutes medical advice, a prescription, or a recommendation from a physician. The reconstitution, dosing, and protocol information above reflects ranges commonly cited in published research and clinician-directed protocols — it is provided as reference material only, not as instructions, an endorsement of off-label use, or a substitute for individualized medical evaluation.

Customers should do their own research and consult their own physician before considering any peptide protocol. Whether a given compound is appropriate for an individual — and at what dose, for what duration, and alongside what monitoring — is a decision that only a licensed clinician with knowledge of that individual's medical history, current medications, and conditions can make.

The platform and the author make no claim that any compound described here is safe, effective, or appropriate for any particular person or purpose, and accept no responsibility for outcomes arising from self-directed use of the information.